-

John C. Landon, Founder of BIOQUAL, Inc., Passes Away at the Age Of 84

ROCKVILLE, Md.--(BUSINESS WIRE)--Dr. John C. Landon, past president, CEO and former chairman of the board of BIOQUAL, passed away Sunday, January 10, 2021, at the age of 84. John was born and raised in Hornell, New York, and went on to earn a B.A. degree in biology from Alfred College (class of 1959) and M.S. and Ph.D. degrees in biology from The George Washington University in 1962 and 1967, respectively. John worked for most of his career in Maryland, but spent his summers in Brewster, Massachusetts, which he retired to in 2013.

John had a long and distinguished career in biology. He began his career at the National Cancer Institute working in cancer virology, then went on to join Litton Bionetics from 1965 until 1975, where he became the Science Director of the Frederick Cancer Research Center. In 1975, he became President and Director of Mason Research Institute, a subsidiary of Edgerton, Germeshausen, and Grier, Inc., now known as Perkin Elmer. In 1982, he became president of BIOQUAL, originally named Diagnon Corporation, a biomedical research corporation that provided contract services to the National Institutes of Health, as well as academic and commercial clients. He led BIOQUAL for more than 30 years as President and CEO, and was a key figure in its growth and development from a one-product company to a $20M + life sciences corporation by the time of his retirement. BIOQUAL continues to thrive today, providing innovative research support for improved global health and playing a key role in testing vaccines and therapeutics for COVID-19 and many other diseases.

www.bioqual.com

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)

BIOQUAL, Inc.

OTC Pink:BIOQ

Release Versions

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)

More News From BIOQUAL, Inc.

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pink Limited): Three Months Ended August 31,   2025   2024   Revenue $ 9,855,399   $ 11,770,482     Loss Before Income Tax $ (343,432 ) $ (931,825 )   Net Loss $ (248,832 ) $ (675,325 )   Basic Earnings per Share of Common Stock $ (0.28 ) $ (0.76 )   Diluted Earnings per Share of Common Stock $ (0.28 ) $ (0.76 )   Weighted Average             Number of Shares Outstanding             For Basic Earnings Per Share   894,416     89...

BIOQUAL Presents Financial Results for Fiscal Year 2025

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):     2025     2024   Revenue $ 48,867,753   $ 58,590,949   (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447   Net (Loss) Income $ (1,048,154 ) $ 483,481   Basic Earnings per Share of Common Stock $ (1.17 ) $ .54   Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54   Weighted Average           Number of Shares Outstanding           For Basic Earnings Per Share   894,416     894,416   Weighted Average...

BIOQUAL Announces the retirement of Dr. Mark G. Lewis as President and CEO of the company

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets): Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. “The entir...
Back to Newsroom